BioWorld Today here continues its occasional listings of government agencies seeking industrial licensees to commercialize biotechnology-related research and development inventions. Commercialization rights are offered by the National Institutes of Health, Office of Technology Transfer (OTT). Announcements of the following sixteen licensing opportunities have been submitted to the Federal Register.

To obtain licensing information and copies of the U.S. patent issuances or applications listed below, contact the OTT licensing specialists indicated.

FOOD AND DRUG ADMINISTRATION

Oncoimmunins

Oncoimmunin-L is a T cell mitogen that is similar to human leukocyte elastase inhibitor. Oncoimmunin-M is a myeloid differentiation inducing agent that is similar to human lactate dehydrogenase M. Both factors are tumor-derived soluble proteins whose appearance in the blood may indicate the presence of tumors or metastatic disease. Their bioactivities suggest they may be useful therapeutics for cancer and immune system diseases.

U.S. Patent: 5,364,619

Issued: 11/15/94

Inventors: Packard, B., et al.

Contact: Jaconda Wagner, (301) 496-7735, ext. 284

Hepatitis C Antivirals

A permanent human cell line has been developed which contains an expression vector that directs the cells to synthesize non-structural hepatitis C proteins. The expressed protease, helicase, and RNA polymerase are crucial for virus replication. Potential antivirals directed against these enzymes can be assayed in this system.

OTT Reference: E-012-98/0

Inventors: Sherman, G., et al.

Contact: Carol Salata, (301) 496-7735, ext. 232

NATIONAL CANCER INSTITUTE

Recombinant Peptide HIV Vaccine

An HIV vaccine using synthetic or recombinant peptides has been developed. Unlike previous vaccines, the peptides used in this vaccine do not include regions of glycoprotein (gp)160 that contribute to acceleration of infection or the development of immune deficiency. Six multideterminant peptide regions of overlapping peptides are recognized by T cells from humans of multiple HLA types. In Phase I clinical trials, this vaccine induced high titers of neutralizing antibodies, cytotoxic T cells, and helper T cells specific for the HIV-1 (gp)160 envelope protein while avoiding the safety risks of live or killed viruses.

Application: 08/060,988

Filed: 5/14/93

Inventors: Berzofsky, J.A., et al.

Contact: Robert Benson, (301) 496-7056, ext. 267

Mucosal Immunity Induced By An HIV Vaccine

Intrarectal administration of an HIV-1 peptide vaccine induces an antigen-specific, protective cytotoxic lymphocyte response in the mucosal and systemic immune system that is much greater than that which occurs with intranasal administration. The immune response is enhanced by co-administration of a mucosal adjuvant such as cholera toxin, and is further enhanced by intrarectal administration of interleukin-12. This vaccine protects mice against an intrarectal challenge with recombinant vaccinia virus expressing HIV glycoprotein (gp)160.

Application: 60/058,523

Filed: 2/17/98

Inventors: Berzofsky, J.A., et al.

Contact: Robert Benson, (301) 496-7056, ext. 267

Missence CCR2 Gene Allele Results
In Delayed Progression To AIDS

A specific variant of chemokine receptor CCR2, a co-receptor for HIV-1, resulting from missense mutation that makes a conservative amino acid substitution within the first transmembrane region, is associated with delayed progression to AIDS in HIV-1 infected individuals. This variant is independent of one found in the chemokine receptor CCR5, which is also associated with delayed progression to AIDS. This CCR2 variant occurs in 10 to 29 percent of individuals in all ethnic groups and nearly 40 percent contain at least one of these variants, thus making these variants potentially useful in the development of diagnostics and therapeutics.

OTT Reference: E-209-97/0

Filed: 8/14/97

Inventors: Dean, M., et al.

Contact: Elaine Gese, (301) 496-7056, ext. 282

Inhibiting Human Papillomavirus With Antisense

Antisense oligonucleotides having a phosphorothioate back-bone structure and sequences complementary to a specific sequence in the E6 gene of human papillomavirus 16 inhibit this virus. These antisense oligos may be useful as antiviral therapeutics.

Application: 08/929,140

Filed: 9/5/97

Inventors: DiPaolo, J.A., et al.

Contact: Carol Salata, (301) 496-7735, ext. 232

Aspirin Metabolites Protect
Against Chemotherapy Drug Toxicity

Hydroxybenzoate metabolites and analogs, which are derivatives of aspirin, can be used to treat oxidative stress and damage in tissues. In particular, the cytotoxic side effects of cancer chemotherapy agents, including adriamycin, can be treated using these compounds.

Application: 60/039,375

Filed: 3/20/97

Inventors: Mitchell, J.B., et al.

Contact: Leopold J. Luberecki, Jr., (301) 496-7735, ext. 223

NATIONAL HEART, LUNG AND BLOOD INSTITUTE

Ultrasound System For Fast Formation Of Images

An ultrasound system has been developed based on the interaction between a static magnetic field and conductive groups in the imaged sample under electrical excitation. This system does not depend on contrast based solely on acoustic properties. It dispenses with acoustic beam excitation, thus making it suitable for fast multidimensional image formation with wide angle signal reception. A working prototype is being tested and is available for commercial development.

OTT Reference: E-067-96/0

Filed: 7/3/97

Inventor: Wen, H.

Contact: John Fahner-Vihtelic, (301) 496-7735, ext. 270

NATIONAL INSTITUTE ON AGING

Treating Diabetes With (GLP)-1 and Exedin-4

The gut hormone glucagon-like peptide (GLP)-1 increases insulin production, thus reducing the need for insulin injection in clinical trials of patients with both Type I and II diabetes, but its pharmaceutically effective blood half-life is only approximately five minutes. Exedin-4, which is isolated from the venom of the Gila monster, is a potent agonist of GLP-1 and also increases insulin production when administered alone. Exedin-4 has a blood half-life of approximately ten hours. Experiments aimed at finding the combinations of these substances that provide the longest therapeutic effect are ongoing.

OTT Reference: E-251-97/0

Inventors: Egan, J., et al.

Contact: Charles M. Maynard, (301) 496-7735, ext. 243

Adipose Transmembrane Protein For Diabetes, Aging

A seven transmembrane protein and corresponding complementary DNA (cDNA) clone have been isolated from mouse adipose tissues. This protein is overexpressed in the epididymal tissues of diabetic and older mice, thus indicating its potential usefulness in diabetes and aging research and in their therapeutic treatment.

OTT Reference: E-213-97/0

Filed: 6/19/97

Inventors: Montrose-Rafizad, C., et al.

Contact: Stephen Finley, (301) 496-7056, ext. 215

NATIONAL INSTITUTE OF ALLERGY
& INFECTIOUS DISEASES

Fusion Accessory Factor Associated With HIV Infection

A novel chemokine G protein coupled receptor-like protein appears to be a fusion cofactor for both macrophage- and T cell-trophic HIV-1. Cells expressing this factor and CD4 are capable of fusing with HIV-1 infected cells. Since this cofactor appears to be directly involved in HIV infection and the progression to AIDS, inhibitors that are developed may be useful in preventing or treating HIV-1 infection.

OTT Reference: E-087-97/0

Filed: 3/31/97

Inventors: Farber, J., et al.

Contact: Elaine Gese, (301) 496-7056, ext. 282

CC Chemokine Receptor-1 Knockout Mice

A transgenic knockout mouse lacking the CC chemokine receptor 1 has been developed. This receptor normally binds the chemokines MIP-1 and RANTES. Its other biological functions are being studied. These knockout mice are available for licensing via a Biological Materials License.

OTT Reference: E-234-97/0

Inventors: Gao, J.-L., et al.

Contact: Elaine Gese, (301) 496-7056, ext. 282

Functional Promoter For CC Chemokine
Receptor-5 In HIV Research

The functional promoter sequence for CC chemokine receptor-5, which functions as a cofactor for HIV binding, has been identified. Therefore, blocking or suppressing the expression of this receptor using inhibitors that bind its gene promoter could result in the development of agents that prevent or treat HIV infection.

OTT Reference: E-222-97/0

Inventor: Guignard, F.

Contact: Elaine Gese, (301) 496-7056, ext. 282

CC Chemokine Receptor-8 in HIV Research

CC chemokine G protein coupled receptor-8, which binds chemokine I-309, is a co-receptor for HIV-1 that is expressed in both monocytes and the thymus. Therefore, blocking or suppressing the expression of this receptor could result in the development of agents that prevent or treat HIV infection.

OTT Reference: E-220-97/0

Filed: 7/29/97

Inventors: Tiffany, H.L., et al.

Contact: Elaine Gese, (301) 496-7056, ext. 282

Malarial Plasmodium Chloroquinone
Resistance Gene

A Plasmodium falciparum gene conferring resistance to chloroquinone has been identified. This gene and its expressed product can be used in developing new antimalarial agents to overcome the increasingly seen resistance to chloroquinone treatment.

Application: 60/058,895

Filed: 9/15/97

Inventors: Wellems, T.E., et al.

Contact: Carol Salata, (301) 496-7735, ext. 232

NATIONAL INSTITUTE OF ARTHRITIS &
MUSCULOSKELETAL & SKIN DISEASES

Recombinant Protein Domain Display In Phages

A filamentous phage display system is described in which the proteins of interest that are displayed are covalently connected to dispensable capsid polypeptides that are, in turn, bound to a surface lattice protein. Proteins of varying length and character can be displayed for immunoisolation using this system.

Application: 08/837,301

Filed: 4/11/97

Inventor: Steven, A.C.

Contact: Carol Salata, (301) 496-7735, ext. 232

— Compiled by Chester A Bisbee

No Comments